Cerivastatin, genetic variants, and the risk of rhabdomyolysis. - Wikidata - awgldk - TriplyDB

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

http://www.wikidata.org/entity/Q34792178

about

SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink Cardiovascular pharmacogenomics: current status and future directions Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation Phenotype standardization for statin-induced myotoxicity Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis PharmGKB summary: very important pharmacogene information for RYR1 Rank-based genome-wide analysis reveals the association of ryanodine receptor-2 gene variants with childhood asthma among human populations Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy.Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel SLCO1B1 Polymorphisms and Statin-Induced Myopathy.OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions.Integrative genomics strategies to elucidate the complexity of drug response.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Clinical perspective: statins and the liver--harmful or helpful?Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.Pharmacogenomics of lipid-lowering therapies.Systems pharmacology modeling: an approach to improving drug safety.Genetics and personalized medicine--a role in statin therapy?Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity.Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Statins, Muscle Disease and Mitochondria.GATM locus does not replicate in rhabdomyolysis study.Mangravite et al. reply.Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.Fast permutation tests and related methods, for association between rare variants and binary outcomes.Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.Application of Multiplex Biomarker Approaches to Accelerate Drug Discovery and Development.Solute Carrier (SLC) Family Transporters

P2860

Q24598793-3E73A38F-AB76-457A-AE69-C1789D7465CC Q26801183-6A2FC9F4-0AA6-4CAC-BD18-4026B279ED74 Q26823434-9B5356B6-F7CE-4DFF-BA41-F83DDC708E6E Q27011524-3BF49313-6E07-4985-9E73-090B36D8BAA2 Q27020935-0C9ADE81-7005-445A-9694-00BA6D72E0CD Q28070052-1E4B9FF2-0FA1-4BB0-B904-C18379E5BF98 Q28074804-62E1E2E2-02C2-46A4-8ADD-D892367161A4 Q29417027-DC2255CE-E28F-481F-AFE8-A9F003FFECF4 Q30489175-A714800E-2582-4613-A14C-06C64352F1E7 Q31043647-AA68AF18-FBB9-4404-968C-EDBFE4BDD596 Q34608646-CFB3A8D6-6353-4B8A-9719-71625D06FE89 Q34680467-428A1CB1-B50B-4DB3-8EE3-312211F1266E Q35232279-6D9656B9-4B04-4FDE-8A9D-2AC3602CCA9D Q35669829-939D5C38-A9C6-4720-8E5F-D81BE4819580 Q35915932-C463B7AD-F05F-44A7-AEBD-A0F52D8D68DB Q36256049-F4A6C030-AA77-4E77-8E59-759375D0D694 Q36808178-FE3FA12F-544E-44CF-A589-3044D1540993 Q37316562-8A829936-FECF-4B62-9620-7A89BA50842F Q37410969-761750F8-999C-42D8-B29F-D83CDFD5AF5F Q37489569-80B11410-4A1A-4753-8AA7-891B84A8EFBD Q37678095-A207FBF6-E449-41F9-A061-D565B32FA1E3 Q37961088-06D08CF9-9B58-4F4C-984A-E995F5A2C950 Q38003174-D6B6A8B1-57D4-417B-9125-82C1A40A110F Q38009719-FCAC2163-656D-4D12-B103-7B5EBCBF1D63 Q38097339-4030C607-1D43-4396-8BAD-37954B85B5F5 Q38112823-1CF8D087-243D-4D64-9B19-31895E40531A Q38153621-C9FECA9D-EF5A-4863-85DF-E845BBDB895A Q38167710-BF0622C7-CD41-436F-9B57-FB7D932B4ADE Q38613161-70FFE635-D993-4D8E-AB42-ED73BCDB2A75 Q38644316-6C17CE58-E3F8-42E5-8DFC-D324B95B5895 Q38809604-186FEB30-17AF-4171-BB4B-AE4CA79F1652 Q41552418-7843CFE6-DF87-42E9-963F-800BCF646E2B Q43004038-03067D23-54CC-4067-8E56-F8AD784BC5CB Q43559413-F2AEB450-5AFE-4C78-8D50-446E6DA3059E Q45337198-30B3D34B-4C2E-42C5-92DE-76A7205E5BF4 Q47293339-36B00964-91D3-4090-96BA-74B52E31C627 Q47566249-971C08B2-84FE-4BE7-BC09-5D1EF955C2DF Q47763396-10066241-F5CF-40F1-BE23-DF4F3139DB3A Q51091535-B493ECC6-4D3D-4711-AD4B-EAE0FC73792F Q57684555-69C2AF3E-C49C-4A50-8E38-E303F69E2D97

P2860

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

http://www.wikidata.org/entity/Q34792178

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@ast

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@en

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@nl

type

label

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@ast

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@en

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@nl

prefLabel

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@ast

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@en

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@nl

P1433

Q34792178-1D484019-87B0-41E9-B687-DD4BE3820485

P1476

Q34792178-EEB54A49-1F62-40A5-9750-859850BAB9BD

P2093

Q34792178-0B399F71-AE63-4856-B378-14DE977B96C3

Q34792178-0C8D2633-B8B6-4D5A-9C4E-A5B16A5288F4

Q34792178-1C9B719B-680B-40A4-9287-CF2DBA3CE50C

Q34792178-1CD667CB-2DB9-457A-8351-C2E5973952F6

Q34792178-47F3757C-9D95-41B9-8464-28096DD3A655

Q34792178-4B1CF545-D10C-4861-A3B3-A294C91512FF

Q34792178-63445640-8C3E-4405-8173-BE4D466BACEF

Q34792178-6954BBE8-56ED-4563-9EA4-A7505D17DDDD

Q34792178-7DB0167D-D97C-433B-83DF-425278DD597F

Q34792178-81A60CBB-5D33-4D05-AB47-D46F902F0FAE

P2860

Q34792178-05EA987F-2084-4FBC-AEFF-63BD303D7CE1

Q34792178-09FC050E-6B61-4620-B25C-C316E00D72BC

Q34792178-169B9A56-07B5-4713-BDED-5BF0E220E25B

Q34792178-1C1A800F-7204-4151-ADE1-F1DF46123B71

Q34792178-2217E938-C457-4B3E-A653-0E381227E5AB

Q34792178-234C4353-33B1-4DC2-8DA0-A481574A66A4

Q34792178-2E0FBF76-7A79-4C10-BADC-362FCCFEACB6

Q34792178-3833FDD4-673F-4DDC-AEDA-724AF5A7E0F9

Q34792178-3845906D-B97B-4B08-B185-BBFB55B01A3C

Q34792178-390872CB-F51D-44AF-A332-9A169776704B

P304

Q34792178-857F215A-98DA-4B9E-A0DC-494593FD1409

P31

Q34792178-CE340055-89C4-476E-ADBE-3322125FC277

P356

Q34792178-2DDE8A00-8675-46A0-AAE2-78BCD10B7490

P433

Q34792178-B4B9CFD4-D767-4F51-B598-D621ABE7BD21

P478

Q34792178-3B6ED5F8-1B3E-4994-8410-D8C7002DF623

P50

Q34792178-0E341616-C816-405F-A0D2-CEF6A2E89125

Q34792178-5AF66806-5C3B-4B48-9C65-85CB3BCCEE67

Q34792178-7BFA5BD2-6F6D-4F4D-95F7-B60D826DBE87

Q34792178-B9C99C22-1F5F-4D08-9DD3-EFE6349621EF

Q34792178-C9EFAB03-346D-4F82-9C29-479262A50D8F

P577

Q34792178-F9701D36-DFDB-486A-A925-CD6876374C9C

P698

Q34792178-B7C9A7C0-0224-4376-AD51-4B6B08A7FD2A

P932

Q34792178-4C9C7AAF-BB63-4885-BE97-3E63806E4EB7

P356

FPC.0B013E328343DD7D

P1433

Pharmacogenetics and Genomics

P1476

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

@en

P2093

Bani Tamraz

http://www.w3.org/2001/XMLSchema#string

Barbara McKnight

http://www.w3.org/2001/XMLSchema#string

Cashell E Jaquish

http://www.w3.org/2001/XMLSchema#string

Deanna L Kroetz

http://www.w3.org/2001/XMLSchema#string

Guo Li

http://www.w3.org/2001/XMLSchema#string

Hisayo Fukushima

http://www.w3.org/2001/XMLSchema#string

Jon P Durda

http://www.w3.org/2001/XMLSchema#string

Ken Rice

http://www.w3.org/2001/XMLSchema#string

Kent D Taylor

http://www.w3.org/2001/XMLSchema#string

Kristin D Marciante

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2)

Association between statin-associated myopathy and skeletal muscle damage

Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia

Malignant hyperthermia: update on susceptibility testing

Molecular cloning of cDNA encoding the Ca2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum

The Cardiovascular Health Study: design and rationale

Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data.

Clinical pharmacokinetics of cerivastatin.

P304

280-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E328343DD7D

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Jerome I Rotter

Susan R Heckbert

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21386754

http://www.w3.org/2001/XMLSchema#string

P932

3076530

http://www.w3.org/2001/XMLSchema#string